Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report

索玛鲁肽相关加重青少年女性非典型神经性厌食症:病例报告

阅读:1

Abstract

Anorexia nervosa is characterised by the fear of gaining weight and a disrupted relationship with food but atypical if the body mass index is within normal limits. Semaglutide is a glucagon-like peptide-1 receptor agonist, indicated in patients with diabetes type 2 and obesity. An adolescent girl was diagnosed with atypical anorexia nervosa. She had a fear of gaining weight, she increased her exercise and decreased her caloric intake. The adolescent was admitted to the paediatric ward with bradycardia and pericardial effusion. During her hospital stay she admitted to having used semaglutide. Semaglutide was prescribed by her general practitioner because she was previously on the verge of being overweight with weight-related dysphoria. After 3 months she stopped using semaglutide, she kept losing weight. The adolescent girl went back to her normal life but after a panic attack caused by gaining 1 kg, she was admitted to an eating disorder ward. Semaglutide can affect mental health in patients who are prone to mental disorders. The importance of restrictively prescribing semaglutide for the right indication with caution and strict follow up is emphasised.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。